Pre-Made Pepinemab biosimilar, Whole mAb, Anti-SEMA4D Antibody: Anti-A8/BB18/C9orf164/CD100/COLL4/GR3/M-sema-G/SEMAJ/coll-4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pepinemab is a humanised IgG4 monoclonal antibody against the semaphorin 4D (SEMA4D; CD100), being developed by Vaccinex for the treatment of multiple cancers, Alzheimer’s disease and Huntington’s disease.